
1. On a GAAP basis, fourth-quarter Abbott sales increased 7.2%.
2. On a GAAP basis, full-year 2021 Abbott sales increased 24.5%.
3. Full-year 2021 GAAP diluted EPS from continuing operations was $3.94.
4. Full-year 2021 diluted EPS from continuing operations on a GAAP basis reflects 58% growth.
5. On a GAAP basis, full-year 2021 Medical Devices sales increased 21.9%; Diagnostics sales increased 44.8%; Nutrition sales increased 8.5%; Established Pharmaceuticals sales increased 9.6%.
6. Abbott projects full-year 2022 diluted earnings per share from continuing operations under GAAP of at least $3.43.
7. Abbott forecasts specified items for the full-year 2022 of $1.27 per share primarily related to intangible amortization, restructuring and cost-reduction initiatives, expenses associated with acquisitions and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would at least reflect nearly 43% growth versus prior year.
8. On a GAAP basis, full-year 2022 projected adjusted diluted EPS from continuing operations reflects 67% growth compared to 2019. Full-year 2019 diluted EPS from continuing operations was $2.06 on a GAAP basis and $3.24 on an adjusted basis.
9. On a GAAP basis, Medical Devices full-year 2021 sales increased 17.0% compared to sales in 2019.
10. On a GAAP basis excluding COVID-19 testing-related sales, fourth-quarter Diagnostics sales increased 8.7% on an organic basis.*

**FORWARD-LOOKING STATEMENTS**

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

---

**FOURTH-QUARTER AND FULL-YEAR 2021 RESULTS**

**TOTAL COMPANY**

<table>
<thead>
<tr>
<th><strong>WORLDWIDE SALES</strong></th>
<th><strong>GROWTH ON AN ORGANIC BASIS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Q4</strong> $11.5B</td>
<td>+7.7%*</td>
</tr>
<tr>
<td><strong>FULL YEAR</strong> $43.1B</td>
<td>+22.9%*</td>
</tr>
</tbody>
</table>

**FULL YEAR** $5.21* ADJUSTED DILUTED EPS

---

**FULL-YEAR 2021: KEY BUSINESS UNITS**

<table>
<thead>
<tr>
<th><strong>GROWTH ON AN ORGANIC BASIS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MEDICAL DEVICES</td>
</tr>
<tr>
<td>DIAGNOSTICS</td>
</tr>
<tr>
<td>NUTRITION</td>
</tr>
<tr>
<td>ESTABLISHED PHARMACEUTICALS</td>
</tr>
</tbody>
</table>

---

**BUSINESS HIGHLIGHTS**

**LEADING IN HEALTH TECH**

- $1.0B Q4 FREESTYLE LIBRE® SALES
  - Now approaching 4 million users globally

- 15.8% GROWTH IN MEDICAL DEVICES on an organic basis* compared to pre-pandemic sales in 2019

**ADVANCING OUR R&D PIPELINE**

- New product introductions and approvals across our portfolio, including several in large, fast-growing markets
- Highlights include expanded reimbursement coverage for MitraClip® and launch of NeuroSphere™ Virtual Clinic for remote treatment of chronic pain or movement disorders

**ISSUED FULL-YEAR 2022 EPS GUIDANCE**

At least $4.70* in adjusted diluted EPS

Reflects 45%* growth compared to 2019

---

**FORWARD-LOOKING STATEMENTS**

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.